Stoke Therapeutics, Inc. Common Stock (STOK)
Stoke Therapeutics, Inc. is a biotechnology company focused on developing therapies for genetic disorders by leveraging its proprietary platform to modulate gene expression. The company aims to address underlying genetic causes of diseases through precision oligonucleotide-based interventions.
Company News
Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish ...
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics' stock soars as positive data shows potential for their lead drug candidate, STK-001, in treating Dravet syndrome. Read here for more details.
A more selective small-cap index has consistently outperformed the Russell 2000
This small-cap biotech might be a hidden gem.